DNA amplification and neoplastic transformation mediated by a herpes simplex DNA fragment containing cell-related sequences

The transforming potential of the herpes simplex virus type 2 (HSV-2) BamHI fragment E (map position 0.533-0.583) encoding the 140-kDa ribonucleotide reductase was assayed by transfection in established Rat-2 cells. Foci of refractile, morphologically distinguishable cells were induced at lower efficiency and after a longer incubation period as compared to the human tumor oncogene EJ-Ha-ras. Focus-derived BamHI fragment E-transformed cell lines formed medium-to-large (0.1-0.25 mm) colonies in soft agar and were tumorigenic in immunocompetent syngeneic rats. Southern blot analysis of normal rat DNA after EcoRI digestion revealed specific DNA segments homologous to HSV-2 BamHI fragment-E DNA. In BamHI fragment E-transformed and tumor-derived lines, about 8- to 30-fold amplification was detected in a subset of the specific HSV-related DNA segments. In addition, extrachromosomal DNA was isolated from transformed cells by plasmid rescue and contained the left-hand 70% of HSV-2 Bam HI fragment E fused to rat DNA. These results indicate the presence in normal cells of nonrepetitive DNA segments, related to the transforming HSV-2 fragment, that can be targeted for genetic alterations associated with neoplastic transformation.

Left ventricular function after a single large dose of verapamil

The effects of a single large dose of verapamil on left ventricular (LV) function were evaluated noninvasively in 18 chronically hypertensive patients. Each patient was given a single oral dose of verapamil, 240 mg, before and after which arterial blood pressure was measured and an echocardiogram and a phonomechanocardiogram were obtained. Reactional symmetrical myocardial hypertrophy was seen in all patients on the first echocardiogram. Results showed that heart rate was not significantly altered, but there were significant decreases (p less than 0.01) in systolic blood pressure (183.89 to 127.56 mm Hg) and diastolic blood pressure (101.11 to 77.67 mm Hg). The following parameters were also significantly decreased (p less than 0.01): LV ejection time (294.56 to 274.22 ms), LV diastolic diameter (45.78 to 43.99 mm), percentage change in LV diameter (33 to 27.83%), mean velocity of circumferential fiber shortening (1.12 to 1.02 cir/s), posterior wall contraction velocity (40.83 to 36.28 mm/s), LV end-diastolic volume (97.78 to 86.89 cm3), ejection fraction (0.70 to 0.62), stroke volume (70 to 55 cm3) and cardiac output (4.7 to 4 liters/m). Three parameters were significantly increased (p less than 0.01): preejection period (104.06 to 112.06 ms), preejection period: LV ejection time ratio (0.35 to 0.41) and end-systolic volume (29.28 to 32.33 cm3). It is concluded that a single oral dose of verapamil, 240 mg, is highly efficient in lowering arterial blood pressure in chronically hypertensive patients and in reducing the peripheral resistance and LV performance indexes.

Cross-sectional echocardiographic features of "absent" pulmonary valve. Report of two cases

"Absence" of the pulmonary valve was recognized by cross-sectional echocardiography in two infants having relatively atypical clinical manifestations for this cardiac malformation. Both had associated lesions: tetralogy of Fallot and ventricular septal defect, respectively, which were also detected by this non-invasive technique. The findings which strongly suggested the diagnosis were the presence of a ridge of rudimentary pulmonary valvular tissue at the level of the pulmonary annulus and the aneurysmal dilation of the pulmonary arteries. The short axis view at the level of the great arteries was the best approach for visualization of these anatomical abnormalities. The parasternal long axis and sub-costal four-chamber views were also helpful in detecting the associated lesions. In both cases the diagnoses were confirmed at autopsy.

[Fibrocystic disease of the pancreas: a presentation feature. Anatomopathological report]

Five patients with CF (cystic fibrosis) dead between 1974 to 1982 at ages ranging from one to six months are presented. All of them showed edema, hypoalbuminemia and anemia in a severely compromised clinical situation, and failure to gain weight in spite of being breast-fed in the first weeks of life, in four of them. All of them were second or third degree malnourished babies (Gomez classification) at admission. Five children presented edema, two severe, two moderate and one mild. Hematocrit values ranged from 19% to 39% (means 26.4%), and albuminemia from 1.60 to 3.00 g/% (means 2.14 g/%). Two patients presented antecedents of dead brothers. All of them received substitution therapy with pancreatic enzymes. The children dead within seven and seventeen days of admission (means ten days) of broncho-pulmonar disfunction. In this work, we wish to call the pediatrician's attention about the importance of making this diagnostic presumption in the first months of the life.

Metabolism of cadaverine and pipecolic acid in brain and other organs of the mouse

Cadaverine and pipecolic acid metabolism was investigated in vitro in several organs of the mouse by measuring 14CO2 formation from labeled precursors. The liver showed the highest formation of 14CO2 from [1,5-14C]-cadaverine, whereas brain demonstrated a much lower formation. Anaerobiosis or inhibition of monoamineoxidase (MAO) activity significantly reduced 14CO2 formation in every organ, but inhibition of diamine oxidase (DAO) activity had no effect in brain and kidney. Piperidine was formed from cadaverine in vitro only in the large intestine and its content. This formation is probably of bacterial origin. Under a variety of experimental conditions we were unable to demonstrate any formation of piperidine in brain from cadaverine. Biosynthesis in vitro of [3H]-piperidine from D,L-[3H]-pipecolic acid was very low in brain and kidney. With the exception of brain and kidney, no other organs showed any formation of [3H]-piperidine. Neither MAO nor DAO inhibition influenced [3H]-piperidine formation in the large intestine with its content. Following 1 hr incubation at 37 degrees C under aerobic conditions, the levels of [14C]-pipecolic acid and [3H]-piperidine recovered from mouse brain homogenate did not indicate any significant degradation of these two substances. Our results suggest that under in vitro conditions, cadaverine is not a precursor of piperidine in brain, liver, heart, and kidney and that only very low levels of piperidine can be formed from pipecolic acid in brain. Outside the brain, formation of piperidine from pipecolic acid is detectable only in kidney and in the content of the large intestine. The latter is probably of bacterial origin. Our results do not support previous findings from other authors on an endogenous origin of piperidine in brain from cadaverine and pipecolic acid, and they suggest that a) cadaverine is not a precursor of piperidine in brain, b) the conversion of pipecolic acid into piperidine in the brain does not constitute a major metabolic pathway, and c) the main source of piperidine in the CNS may be of nonneural origin.

Accumulation and metabolism of pipecolic acid in the developing brain of the mouse

In newborn mice, following i.p. injections of D,L-[3H]PA (pipecolic acid, 28 micrograms/kg), accumulation of radioactivity continues to increase up to 24 h. In adults, radioactivity peaks at 5 min and remains approximately constant up to 5 h, and then declines slowly to 24 h. Fifteen-day-old mice follow the newborn pattern, while 30-day-old mice show the same trend as the adult. Radioactivity in plasma shows essentially the same pattern of accumulation in adult and newborn animals with some quantitative differences. Secretion of radioactivity in the urine is significantly higher in the adult than in the newborn during the interval between 10 min and 5 h. Accumulation of radioactivity at 24 h in the newborn brain shows a preferential localization to the olfactory bulb, the anterior telencephalon and the diencephalon. Two hours after the i.p. injection, approximately 70% of the radioactivity recovered in brain is due to PA. This percentage increases to 75% and 87% at 5 and 24 h respectively. Alpha-aminoadipic acid (alpha-Aaa) a major metabolite of PA was identified in brain extracts at 5 h. The maximal formation of alpha-Aaa in relation to PA occurs approximately at 5 h. No other brain metabolites of PA could be identified with this chromatographic system. The present results show that access of PA to the brain is easier in the newborn mouse than in the adult. In addition, our results demonstrate, for the first time, the presence of PA metabolism in the newborn mouse.

Accumulation, elimination, release and metabolism of pipecolic acid in the mouse brain following intraventricular injection

Following i.c.v. (intracerebral ventricular) injections of D,L-[3H]pipecolic acid (PA), it is reabsorbed from the ventricles and redistributed to various brain regions. The highest accumulation is found in three brain regions ipsilateral to the injection site, hippocampus, neocortex, striatum, and in the diencephalon. Following preloading in vivo, the radioactivity is released from hippocampus slices in the perfusion medium after depolarization induced by high K+. During perfusion with a Ca++ free medium containing EGTA, a significant reduction of release is observed. The radioactivity of D,L-[3H]PA in the brain shows a more rapid phase of decrease from 0 to 2 hours and a slower phase from 2 to 5 hours. At 5 hours, only 28% radioactivity, represented mainly by PA, is left in the brain. Kidney secretion represents the major route of elimination of the injected PA. The presence of alpha-aminoadipic acid both in brain and urine was observed. Probenecid (200 mg/kg) significantly increases the accumulation of i.c.v. injected D,L-[3H]PA in brain and kidney. The presence of a regional accumulation of PA in certain brain regions, its metabolism in brain, its enhanced retention following probenecid administration and its Ca++ dependent release following high K+ stimulation, all constitute indirect evidence for a neuronal localization of this brain endogenous aminoacid.